HPK1 Inhibitors Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Domain | DelveInsight
DelveInsight’s, “HPK1 Inhibitors Pipeline Insight, 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in HPK1 inhibitors pipeline landscape. It covers the HPK1 Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HPK1 Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the HPK1 Inhibitors Pipeline @ https://www.delveinsight.com/sample-request/hpk1-inhibitors-pipeline-insight
Key Takeaways from the HPK1 Inhibitors Pipeline Report
- In May 2025, Treadwell Therapeutics Inc. announced a study will be a first-in-human study evaluating the safety and tolerability of CFI-402411 in subjects with advanced solid malignancies, when CFI-402411 is administered as a single agent or in combination with pembrolizumab. CFI-402411 is an oral pill that blocks the function of HPK1. Blocking HPK1 could stimulate an immune response against the tumor in patients. This immune response could be further enhanced when combined with pembrolizumab. The data obtained from this study will determine the dose and schedule and subject selection for further clinical studies.
- DelveInsight’s HPK1 Inhibitors Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for HPK1 Inhibitors treatment.
- The leading HPK1 Inhibitors Companies such as Treadwell Therapeutics, Stonewise Technology, BeOne Medicines, Arvinas and others.
- Promising HPK1 Inhibitors Pipeline Therapies such as CFI-402411, Pembrolizumab, PRJ1-3024 and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ HPK1 Inhibitors Treatment Drugs
HPK1 inhibitors Overview
HPK1 inhibitors are a class of emerging immunomodulatory drugs targeting hematopoietic progenitor kinase-1 (HPK1), a serine/threonine kinase belonging to the MAP2K family that is predominantly expressed in hematopoietic stem cells. HPK1 acts as a negative regulator of immune cell signaling, particularly in T cells, B cells, and dendritic cells, where it suppresses immune activation and contributes to immune tolerance. Because of this role, HPK1 has become an important target in cancer immunotherapy, as inhibiting this kinase can restore immune function and enhance anti-tumor responses.
HPK1 inhibitors Emerging Drugs
- CFI-402411: Treadwell Therapeutics
CFI-402411 is an investigational small-molecule HPK1 inhibitor developed by Treadwell Therapeutics for cancer immunotherapy. This involves inhibition of HPK1 (MAP4K1), which enhances T-cell activation and promotes anti-tumor immune responses. It is being developed for the treatment of advanced solid tumors, particularly in patients with refractory or metastatic cancers. Currently, CFI-402411 is in Phase I/II clinical development evaluating safety and preliminary efficacy in cancer patients.
- BGB-26808: BeOne Medicines
BGB-26808 is an investigational small-molecule drug developed by BeOne Medicines, it is a potent and selective HPK1 inhibitor designed for cancer immunotherapy. Its mechanism of action involves inhibition of hematopoietic progenitor kinase-1 (HPK1), a negative regulator of T-cell activation, thereby enhancing immune responses against tumors. The drug is being developed for the treatment of advanced solid tumors, both as monotherapy and in combination with the anti-PD-1 antibody tislelizumab. Currently, BGB-26808 is in Phase I clinical development in an ongoing first-in-human study evaluating safety, tolerability, and preliminary efficacy.
- ARV-6723: Arvinas
ARV-6723 is an investigational oral PROTAC degrader developed by Arvinas, designed to target hematopoietic progenitor kinase 1 (HPK1), and represents the company’s first immuno-oncology clinical candidate. Its mechanism of action involves selective degradation of HPK1, a negative regulator of T-cell receptor signaling, thereby enhancing immune activation and promoting anti-tumor responses. The drug is being developed for the treatment of advanced solid tumors, where preclinical studies have shown strong anti-tumor immune activity both as a single agent and in combination with immunotherapies. In terms of historical development, ARV-6723 has so far demonstrated robust preclinical efficacy and immunomodulatory activity, supporting its progression toward clinical evaluation. Currently, ARV-6723 is in the preclinical stage of development for the treatment of advanced solid tumors.
The HPK1 Inhibitors Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of HPK1 Inhibitors with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HPK1 Inhibitors Treatment.
- HPK1 Inhibitors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- HPK1 Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HPK1 Inhibitors market
Explore groundbreaking therapies and clinical trials in the HPK1 Inhibitors Marketed Drugs @ New HPK1 Inhibitors Drugs
HPK1 Inhibitors Companies
Treadwell Therapeutics, Stonewise Technology, BeOne Medicines, Arvinas and others.
HPK1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
HPK1 Inhibitors Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Learn about new HPK1 Inhibitors drugs pipeline developments @ HPK1 Inhibitors Market Drivers and Barriers
Scope of the HPK1 Inhibitors Pipeline Report
- Coverage- Global
- HPK1 Inhibitors Companies- Treadwell Therapeutics, Stonewise Technology, BeOne Medicines, Arvinas and others.
- HPK1 Inhibitors Pipeline Therapies- CFI-402411, Pembrolizumab, PRJ1-3024 and others.
- HPK1 Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- HPK1 Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight’s in-depth HPK1 Inhibitors Pipeline Report today! @ HPK1 Inhibitors Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- HPK1 inhibitors: Overview
- Mechanism of action
- Pipeline Therapeutics
- Therapeutic Assessment
- HPK1 inhibitors – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- BGB-26808: BeOne Medicines
- Preclinical Stage Products
- ARV-6723: Arvinas
- Drug profiles in the detailed report…..
- Inactive Products
- HPK1 inhibitors – Collaborations Assessment- Licensing / Partnering / Funding
- HPK1 inhibitors – Unmet Needs
- HPK1 inhibitors – Market Drivers and Barriers
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hpk1-inhibitors-pipeline-insight
